pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ROCHE · news · pharmadog
← back to ROCHE
News mentioning ROCHE
262
stories
Aug 21, 26
Genentech invests $750M in new factory; Bavarian Nordic delays Lyme trial
endpoints
Aug 21, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Aug 21, 26
STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more
stat
Aug 20, 26
Roche pours $750M into Oregon manufacturing plant as obesity push expands
biospace
Aug 20, 26
Chutes & Ladders—Neumora shuffles leadership ahead of IND
fiercebiotech
Aug 19, 26
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
Aug 13, 26
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
Aug 11, 26
Vaderis hauls in $152M to test an AKT-targeting drug
biopharma dive
Aug 11, 26
IRBs have a problem. Can North Star’s nonprofit model save it?
stat
Aug 10, 26
Labcorp nabs FDA green light for BRAF melanoma diagnostic
fiercebiotech
Aug 10, 26
FDA issues alert in wake of BD recall of faulty needle sets
fiercebiotech
Aug 7, 26
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
Aug 7, 26
Roche adds cyclospora PCR tests as outbreak widens
fiercebiotech
Aug 5, 26
Attovia adds to biotech IPO momentum with $289M offering
biopharma dive
Aug 4, 26
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
Aug 4, 26
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
Jul 31, 26
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
Jul 30, 26
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
Jul 30, 26
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
Jul 29, 26
Caldera, Vidya add to recent flurry of biotech mergers
biopharma dive
Jul 29, 26
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
biopharma dive
Jul 29, 26
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
Jul 28, 26
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
Jul 28, 26
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
biospace
Jul 28, 26
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
Jul 27, 26
RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC
fiercebiotech
Jul 27, 26
STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease
stat
Jul 27, 26
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
Jul 24, 26
Roche cans one Carmot obesity asset as another shows best-in-class potential
biospace
Jul 24, 26
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
fiercebiotech
← prev
page 6 of 9
next →
